Autoimmune Hepatitis Clinical Trial
Official title:
A Phase II, Open-Label, Multi-Center, Prospective, Randomized Study of LCP-Tacro Tablets vs. Azathioprine, in Combination With Corticosteroids, for the Treatment of Autoimmune Hepatitis
An open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily vs. azathioprine, each in combination with prednisone, for the treatment of autoimmune hepatitis (AIH).
An open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety
and tolerability of LCP-Tacro tablets given once daily vs. azathioprine for the treatment of
autoimmune hepatitis (AIH).
Patients with histologically confirmed chronic hepatitis who fulfill criteria established by
the International Autoimmune Hepatitis Group (IAIHG) and Inclusion and Exclusion criteria
will be enrolled after having signed an informed consent document.
Up to 60 patients will be randomized (1:1) to receive treatment with LCP-Tacro + prednisone
vs. azathioprine (AZA) + prednisone.
- LCP-Tacro will be started at 2 mg once daily (q.d.) with weekly measurement of
tacrolimus whole blood trough levels and adjustment of the daily dose of LCP-Tacro to
achieve target tacrolimus levels of 3 - 6 ng/mL. Patients with histological evidence of
cirrhosis and a Model for End-Stage Liver Disease (MELD) score ≤ 8 will commence
LCP-Tacro at a fixed dose of 1 mg once daily, with subsequent dosage adjustments to
maintain tacrolimus trough levels at 3 - 6 ng/mL.
- AZA will be started at 50 - 100 mg (approximately 1 mg/kg) once daily (q.d.).
Patients will also commence treatment with prednisone 30 mg/day for one week, then 20 mg/day
for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06020976 -
Pattern of Autoimmune Hepatitis in Children In Sohag University Hospital
|
||
| Recruiting |
NCT05476900 -
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.
|
Phase 2 | |
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Recruiting |
NCT06250309 -
Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients
|
N/A | |
| Recruiting |
NCT01661842 -
Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis
|
Phase 1/Phase 2 | |
| Terminated |
NCT04339621 -
AIH Risk Stratification With Multiparametric MRI
|
||
| Not yet recruiting |
NCT04371718 -
Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH)
|
Phase 2 | |
| Completed |
NCT02239562 -
sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS
|
Phase 1 | |
| Recruiting |
NCT05569759 -
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
|
Phase 2 | |
| Completed |
NCT02463331 -
Association of Chloroquine and Prednisone as an Alternative Treatment for Autoimmune Hepatitis
|
Phase 4 | |
| Not yet recruiting |
NCT06356506 -
A Study on Factors of Biochemical Response in Autoimmune Hepatitis
|
||
| Terminated |
NCT04203875 -
Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis
|
Phase 1 | |
| Recruiting |
NCT06078098 -
Development of a Autoimmune Hepatitis Patient's Database Linked to a Biological Sample Storage
|
||
| Completed |
NCT00838214 -
Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05810480 -
PredIcting sterOid depeNdEnt livEr injuRy With Polyreactive Immunoglobulin G
|
||
| Recruiting |
NCT03743272 -
Repeatability and Reproducibility of Multiparametric MRI
|
||
| Completed |
NCT03979053 -
Quantitative Magnetic Resonance Imaging to Aid Clinical Decision Making in Autoimmune Hepatitis.
|
||
| Not yet recruiting |
NCT04902807 -
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
|
||
| Recruiting |
NCT04933292 -
A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome
|
Phase 4 | |
| Not yet recruiting |
NCT06455280 -
SIPLIZUMAB in AILD and LT
|
Phase 1 |